Guidant (GDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guidant (GDT)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMS who wrote (59)	12/2/1997 12:55:00 AM
From: B4TheBell	Read Replies (1) of 235

Complete product line offering has been GDT's strategy for a while. They started a division back in mid '95(?) to find emerging technologies to buy and add to their bag of tricks. Their strategic alliance/acquisitions/funding/equity stakes of smaller companies, i.e. EVT, CardioGenesis (since 1993), Micro Therapeutics and EndoTex have shown this to be the case. Seems to be working... Now let's see if 65 becomes support instead of resistance level... Today's spike should add some volatility factor to premium prices, don't you think? I read somewhere recently that institutional interest is @ 85%. Is there anything left for Fidelity? ;-) B4

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next